Catalog# BTL1028
Lot # Check on the product label
Size 100μg
Isotype IgG
Host Rabbit
Reactivity
Human, monkey, dog
Specificity
Detect endogenous level of total Annexin A1 protein.
Product Form Liquid
Immunogen
A synthetic peptide (conjugated to KLH) corresponding to N-terminal residues of human Annexin A1.
Recommend Application
Western Blot (1:1000)
Other applications have not been tested.
The optimal dilutions should be determined by end user.
Storage Instruction
Store at -20°C for 1 year.
Avoid repeated freeze and thaw cycles.
Background
Annexin A1 / Annexin I also known as lipocortin I is a protein that in humans is encoded by the ANXA1 gene. Annexin I belongs to the annexin family of Ca2+-dependent phospholipid-binding proteins that have a molecular weight of approximately 35,000 to 40,000 and are preferentially located on the cytosolic face of the plasma membrane. Annexin I protein has an apparent relative molecular mass of 40 kDa, with phospholipase A2 inhibitory activity. Annexin I has been of interest for use as a potential anticancer drug. It inhibits the NF-κB signal transduction pathway, which is exploited by cancerous cells to proliferate and avoid apoptosis. ANXA1 inhibits the activation of NF-κB by binding to the p65 subunit.
Reference
1. Wallner BP, Mattaliano RJ, Hession C, Cate RL, Tizard R, Sinclair LK, Foeller C, Chow EP, Browing JL, Ramachandran KL (1986). "Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity". Nature 320 (6057): 77–81.
2. Zhang Z, Huang L, Zhao W, Rigas B (March 2010). "Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo". Cancer Res. 70 (6): 2379–88.
Details
Product Center